MedPath

PFIZER INC.

PFIZER INC. logo
πŸ‡ΊπŸ‡ΈUnited States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

A Study Comparing Amounts of 2 Different Forms of Tafamidis (PF-6291826) in the Blood

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2017-08-30
Last Posted Date
2018-05-14
Lead Sponsor
Pfizer
Target Recruit Count
30
Registration Number
NCT03266705
Locations
πŸ‡§πŸ‡ͺ

Pfizer Clinical Research Unit, Brussels, Belgium

A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis

Phase 1
Completed
Conditions
Atopic Dermatitis
Healthy
Interventions
First Posted Date
2017-08-24
Last Posted Date
2019-03-01
Lead Sponsor
Pfizer
Target Recruit Count
32
Registration Number
NCT03260595
Locations
πŸ‡―πŸ‡΅

Medical Corporation Heishinkai OPHAC Hospital, Osaka-shi, Osaka, Japan

A Study to Learn About the Effects of Multiple Doses of Sisunatovir on People With Respiratory Syncytial Virus (RSV) Infection

Phase 2
Completed
Conditions
Respiratory Syncytial Virus Infections
Interventions
Drug: Placebo
Drug: RV521
First Posted Date
2017-08-23
Last Posted Date
2023-07-19
Lead Sponsor
Pfizer
Target Recruit Count
66
Registration Number
NCT03258502
Locations
πŸ‡¬πŸ‡§

hVIVO Services Ltd, London, United Kingdom

6-week Safety and PD Study in Adults With NAFLD

Phase 2
Completed
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Drug: PF-06835919 High Dose
Drug: Placebo
Drug: PF-06835919 Low Dose
First Posted Date
2017-08-22
Last Posted Date
2019-04-04
Lead Sponsor
Pfizer
Target Recruit Count
53
Registration Number
NCT03256526
Locations
πŸ‡ΊπŸ‡Έ

WR-ClinSearch LLC, Chattanooga, Tennessee, United States

πŸ‡ΊπŸ‡Έ

Stand-Up MRI of Miami, Miami, Florida, United States

πŸ‡ΊπŸ‡Έ

Sterling Research Group, Ltd., Cincinnati, Ohio, United States

and more 5 locations

Absorption, Metabolism, Excretion and Absolute Bioavailability

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Absolute Bioavailability
Drug: PF-04965842
First Posted Date
2017-08-15
Last Posted Date
2017-12-21
Lead Sponsor
Pfizer
Target Recruit Count
6
Registration Number
NCT03250039
Locations
πŸ‡³πŸ‡±

PRA Health Sciences, Groningen, Netherlands

Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

Phase 2
Completed
Conditions
Nonalcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis
Interventions
Drug: Placebo
Drug: PF-05221304
First Posted Date
2017-08-14
Last Posted Date
2020-12-09
Lead Sponsor
Pfizer
Target Recruit Count
305
Registration Number
NCT03248882
Locations
πŸ‡¨πŸ‡¦

Discovery Clinical Services Ltd., Victoria, British Columbia, Canada

πŸ‡ΊπŸ‡Έ

South Denver Gastroenterology, P.C., Englewood, Colorado, United States

πŸ‡ΊπŸ‡Έ

ClinSearch, Chattanooga, Tennessee, United States

and more 134 locations

Understanding Hemophilia A and B Drug Dosage Administration Patterns

Terminated
Conditions
Hemophilia A
Hemophilia B
Interventions
Drug: Hemophilia B standard half-life
Drug: Hemophilia A standard half-life
Drug: Hemophilia B extended half-life
Drug: Hemophilia A extended half-life
First Posted Date
2017-08-14
Last Posted Date
2019-05-20
Lead Sponsor
Pfizer
Target Recruit Count
11
Registration Number
NCT03248141
Locations
πŸ‡ΊπŸ‡Έ

University of Florida College of Medicine, Gainesville, Florida, United States

πŸ‡ΊπŸ‡Έ

Alliance for Childhood Diseases, dba Hemophilia Treatment Center of Nevada, Las Vegas, Nevada, United States

πŸ‡ΊπŸ‡Έ

Cook Children's Medical Center, Fort Worth, Texas, United States

Safety and Efficacy in Adult Subjects With Acute Migraines

Phase 3
Completed
Conditions
Migraine, With or Without Aura
Interventions
Drug: Placebo
Drug: Rimegepant
First Posted Date
2017-08-03
Last Posted Date
2023-02-16
Lead Sponsor
Pfizer
Target Recruit Count
1499
Registration Number
NCT03237845
Locations
πŸ‡ΊπŸ‡Έ

Radiant Research, Inc., Anderson, South Carolina, United States

πŸ‡ΊπŸ‡Έ

Summit Research Network (Oregon), Inc., Portland, Oregon, United States

πŸ‡ΊπŸ‡Έ

Coastal Clinical Research, Mobile, Alabama, United States

and more 38 locations

Safety and Pharmacokinetic Study of PF-06700841 in Japanese Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
Drug: PF-06700841
First Posted Date
2017-08-02
Last Posted Date
2017-10-25
Lead Sponsor
Pfizer
Target Recruit Count
8
Registration Number
NCT03236493
Locations
πŸ‡§πŸ‡ͺ

Pfizer Clinical Research Unit, Brussels, Belgium

Safety and Efficacy Study in Adult Subjects With Acute Migraines

Phase 3
Completed
Conditions
Migraine, With or Without Aura
Interventions
Drug: Placebo
Drug: Rimegepant
First Posted Date
2017-08-01
Last Posted Date
2023-02-16
Lead Sponsor
Pfizer
Target Recruit Count
1485
Registration Number
NCT03235479
Locations
πŸ‡ΊπŸ‡Έ

Neurological Physicians of Arizona/Radiant Research Inc, Gilbert, Arizona, United States

πŸ‡ΊπŸ‡Έ

Clinical Research of Philadelphia, LLC, Philadelphia, Pennsylvania, United States

πŸ‡ΊπŸ‡Έ

Clinical Research Institute, Minneapolis, Minnesota, United States

and more 44 locations
Β© Copyright 2025. All Rights Reserved by MedPath